<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05120349</url>
  </required_header>
  <id_info>
    <org_study_id>D516FC00001</org_study_id>
    <nct_id>NCT05120349</nct_id>
  </id_info>
  <brief_title>A Global Study to Assess the Effects of Osimertinib in Participants With EGFRm Stage IA2-IA3 NSCLC Following Complete Tumour Resection</brief_title>
  <acronym>ADAURA2</acronym>
  <official_title>A Phase III, Double-blind, Randomised, Placebo-Controlled, International Study to Assess the Efficacy and Safety of Adjuvant Osimertinib Versus Placebo in Participants With EGFR Mutation-positive Stage IA2-IA3 Non-small Cell Lung Cancer, Following Complete Tumour Resection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a global study to assess the effects of osimertinib in participants with EGFRm stage&#xD;
      IA2-IA3 non-small cell lung cancer following complete tumour resection.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase III, double-blind, randomised, placebo-controlled, 2-arm, international study&#xD;
      assessing the efficacy and safety of adjuvant osimertinib versus placebo in participants with&#xD;
      stage IA2-IA3 EGFRm Non-Small Cell Lung Cancer, who have previously undergone complete tumour&#xD;
      resection. All participants must have had a tumour which harbours one of the 2 common EGFR&#xD;
      mutations known to be associated with EGFR-TKI sensitivity (Ex19del, L858R).&#xD;
&#xD;
      Eligible participants will be randomised in a 1:1 ratio to one of the 2 intervention arms:&#xD;
      osimertinib 80 mg or matching placebo, once daily for 3 years unless discontinuation criteria&#xD;
      is met.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 30, 2022</start_date>
  <completion_date type="Anticipated">November 2, 2032</completion_date>
  <primary_completion_date type="Anticipated">August 2, 2027</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Disease-Free Survival (DFS) in high-risk stratum</measure>
    <time_frame>From date of randomisation up to approximately 10 years</time_frame>
    <description>DFS is defined as the time from the date of randomisation until the date of disease recurrence or date of death (by any cause in the absence of recurrence), whichever occurs first.&#xD;
Stratification to the high risk stratum will be based on pathologic features assessed by central pathology review during screening.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Disease-Free Survival (DFS) in overall population</measure>
    <time_frame>From date of randomisation up to approximately 10 years</time_frame>
    <description>DFS is defined as the time from the date of randomisation until the date of disease recurrence or date of death (by any cause in the absence of recurrence), whichever occurs first.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS) in high-risk stratum and the overall population</measure>
    <time_frame>From date of randomization up to approximately 10 years</time_frame>
    <description>OS is defined as the time from the date of randomisation until death due to any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK plasma concentrations of osimertinib and of metabolite AZ5104 in overall population</measure>
    <time_frame>From date of randomisation up to approximately 10 years</time_frame>
    <description>Ratio of metabolite-to-osimertinib to be calculated at predose, and at 0.5-2 hours postdose.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Impact of osimertinib versus placebo on physical functioning</measure>
    <time_frame>From date of randomisation up to approximately 10 years</time_frame>
    <description>Assess the impact of osimertinib versus placebo on physical functioning in both the high-risk stratum and the overall population as measured by SF-36 V2 health survey</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Central Nervous System (CNS) Disease-Free Survival (DFS) in both the high-risk stratum and the overall population</measure>
    <time_frame>From date of randomisation up to approximately 10 years</time_frame>
    <description>CNS DFS is defined as the time from randomisation to the time of a CNS lesion (as assessed by investigator) or death due to any cause, regardless of whether the participant withdraws from study intervention or receives other anti-cancer therapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability in overall population</measure>
    <time_frame>From date of randomisation up to approximately 10 years</time_frame>
    <description>AEs graded by CTCAE version 5.0</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">380</enrollment>
  <condition>Non-Small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Osimertinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Osimertinib 80mg, orally, once daily (Dose may be reduced to 40 mg once daily if required at the discretion of the investigator)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matching placebo for osimertinib, orally, once daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Osimertinib</intervention_name>
    <description>The initial dose of Osimertinib 80mg once daily can be reduced to 40mg once daily. Treatment can continue until disease recurrence, unacceptable toxicity or other discontinuation criteria are met.</description>
    <arm_group_label>Osimertinib</arm_group_label>
    <other_name>AZD9291; TAGRISSO</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Matching placebo. Initial dose of 80mg once daily can be reduced to 40mg once daily.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
          1. Male or female, at least ≥ 18 years.&#xD;
&#xD;
          2. NSCLC, of non-squamous histology.&#xD;
&#xD;
          3. Stage IA2 or IA3 disease, based on TNM8 classification.&#xD;
&#xD;
          4. Complete surgical resection (R0) of the primary NSCLC by lobectomy, segmentectomy or&#xD;
             sleeve resection.&#xD;
&#xD;
          5. Complete recovery from surgery at the time of randomisation. Study intervention cannot&#xD;
             commence within 4 weeks following surgery. No more than 12 weeks may have elapsed&#xD;
             between surgery and randomisation for participants.&#xD;
&#xD;
          6. World Health Organization performance status of 0 or 1.&#xD;
&#xD;
          7. Provision of tumour sample for central pathology assessment of pathologic risk factors&#xD;
             and to assess EGFR mutation status prior to randomisation.&#xD;
&#xD;
          8. A tumour which harbours one of the 2 EGFR mutations (Ex19del, L858R) by cobas® EGFR&#xD;
             Mutation Test v2 (Roche Diagnostics) or FoundationOne® test.&#xD;
&#xD;
          9. Minimum life expectancy of &gt; 6 months.&#xD;
&#xD;
         10. Females must be using highly effective contraceptive measures, and must have a&#xD;
             negative pregnancy test prior to start of dosing if of child-bearing potential, or&#xD;
             must have evidence of non-child-bearing potential. Male subjects must be willing to&#xD;
             use barrier contraception.&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
          1. Mixed small cell and non-small cell cancer history.&#xD;
&#xD;
          2. Participants with incomplete (R1/R2) resection, or who have undergone pneumonectomy,&#xD;
             bilobectomy or only wedge resection.&#xD;
&#xD;
          3. Any evidence of severe or uncontrolled systemic diseases, including uncontrolled&#xD;
             hypertension and active bleeding diatheses; or active infection including hepatitis B,&#xD;
             hepatitis C and HIV.&#xD;
&#xD;
          4. History of another primary malignancy except for malignancy treated with curative&#xD;
             intent with no known active disease ≥ 5 years before the first dose of study&#xD;
             intervention and of low potential risk for recurrence.&#xD;
&#xD;
          5. Any of the following cardiac criteria:&#xD;
&#xD;
               -  Mean resting QTc interval &gt; 470 ms, obtained from triplicate ECGs performed at&#xD;
                  screening.&#xD;
&#xD;
               -  Any abnormalities in rhythm, conduction, or morphology of resting ECG,&#xD;
&#xD;
               -  Any factors that increase the risk of QTc prolongation or risk of arrhythmic&#xD;
                  events.&#xD;
&#xD;
          6. History of interstitial lung disease.&#xD;
&#xD;
          7. Inadequate bone marrow reserve or organ function.&#xD;
&#xD;
          8. Any unresolved toxicities from prior therapy greater than CTCAE Grade 1 at the time of&#xD;
             starting study intervention.&#xD;
&#xD;
          9. Prior treatment with any anticancer therapy for NSCLC (including chemotherapy,&#xD;
             radiotherapy, immunotherapy, and EGFR-TKIs).&#xD;
&#xD;
         10. Major surgery or significant traumatic injury within 4 weeks of the first dose of&#xD;
             study intervention.&#xD;
&#xD;
         11. Participants currently receiving medications or herbal supplements known to be strong&#xD;
             inducers of CYP3A4.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jonathan Goldman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UCLA Department of Medicine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Yasuhiro Tsutani, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hiroshima University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jie He, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Cancer Institute and Hospital, Chinese Academy of Medical Sciences (CAMS)</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>AstraZeneca Clinical Study Information Center</last_name>
    <phone>1-877-240-9479</phone>
    <email>information.center@astrazeneca.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Santa Rosa</city>
        <state>California</state>
        <zip>95403</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Towson</city>
        <state>Maryland</state>
        <zip>21204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Mineola</city>
        <state>New York</state>
        <zip>11501</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Fairfax</city>
        <state>Virginia</state>
        <zip>22031</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Beijing</city>
        <zip>100210</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Dublin</city>
        <zip>DUBLIN 4</zip>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Cheongju-si</city>
        <zip>28644</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Gyeonggi-do</city>
        <zip>13620</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Seoul</city>
        <zip>03080</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Seoul</city>
        <zip>07061</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Seoul</city>
        <zip>138-736</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Suwon</city>
        <zip>16499</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kuala Lumpur</city>
        <zip>59100</zip>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kuching</city>
        <zip>93586</zip>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Pulau Pinang</city>
        <zip>10450</zip>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Selangor</city>
        <zip>46050</zip>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Singapore</city>
        <zip>308433</zip>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ankara</city>
        <zip>06010</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bursa</city>
        <zip>16059</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Istanbul</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Izmir</city>
        <zip>35040</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kadıkoy/Istanbul</city>
        <zip>34722</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
    <country>Ireland</country>
    <country>Korea, Republic of</country>
    <country>Malaysia</country>
    <country>Singapore</country>
    <country>Turkey</country>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 3, 2021</study_first_submitted>
  <study_first_submitted_qc>November 3, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 15, 2021</study_first_posted>
  <last_update_submitted>November 17, 2021</last_update_submitted>
  <last_update_submitted_qc>November 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Osimertinib</keyword>
  <keyword>Tagrisso</keyword>
  <keyword>NSCLC</keyword>
  <keyword>Non-small Cell Lung Cancer</keyword>
  <keyword>Resectable</keyword>
  <keyword>EGFRm Positive</keyword>
  <keyword>Adjuvant</keyword>
  <keyword>Stage IA2-IA3</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osimertinib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal.&#xD;
All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.</ipd_description>
    <ipd_time_frame>AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please refer to our disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.</ipd_time_frame>
    <ipd_access_criteria>When a request has been approved, AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool. Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.</ipd_access_criteria>
    <ipd_url>https://astrazenecagroup-dt.pharmacm.com/DT/Home</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

